Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,958.00
Bid: 1,750.00
Ask: 2,222.00
Change: 0.00 (0.00%)
Spread: 472.00 (26.971%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,958.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up

Wed, 24th Oct 2012 09:25

African Barrick Gold: Investec raises target from 485p to 530p, hold rating kept.Aggreko: Seymour Pierce maintains buy rating and 2,500p target.AstraZeneca: Panmure Gordon keeps hold rating and 3,000p target.British American Tobacco: Jefferies keeps buy rating and 3,730p target; Panmure Gordon cuts target from 3,700p to 3,650p, buy rating kept; Investec keeps buy rating and 3,480p target.Centamin: Investec downgrades from buy to hold, target lifted from 95p to 106p.CRH: AlphaValue upgrades from add to buy.CSR: JPMorgan Cazenove downgrades to neutral; UBS ups target from 310p to 330p, neutral rating kept.Diamondcorp: WH Ireland Securities initiates coverage with buy rating and 12p target.Direct Line: JPMorgan Cazenove initiates coverage with neutral rating and 197p target.Experian: Jefferies downgrades from buy to hold, target upped from 1,060p to 1,200p; UBS raises target from 970p to 1,040p, neutral rating kept.Fidessa: Goldman Sachs downgrades to neutral, target cut from 2,050p to 1,580p.Hikma: Jefferies ups target from 875p to 890p, buy rating kept.Home Retail: Panmure Gordon hikes target from 51p to 80p, sell rating kept; Panmure Gordon keeps buy rating and 115p target.HSBC: Investec keeps hold rating and 590p target.Imperial Tobacco: Goldman Sachs upgrades to neutral, target cut from 2,540p to 2,500p.InterContinental Hotels: AlphaValue upgrades from reduce to add; Panmure Gordon keeps hold rating and 1,670p target.National Express: Jefferies maintains buy rating and 300p target; Panmure Gordon keeps hold rating and 250p target.Next: Panmure Gordon ups target from 3,743p to 3,770p, hold rating kept.Ophir Energy: Jefferies keeps buy rating and 800p target.Punch Taverns: Panmure Gordon cuts target from 11p to 7p, hold rating kept.Randgold Resources: Investec downgrades from buy to hold, target lifted from 6,917p to 7,715p.Regus: Panmure Gordon keeps buy rating and 140p target.Spirent Communications: Investec keeps buy rating and 195p target.Sports Direct: Panmure Gordon raises target from 350p to 450p, buy rating kept.Tesco: AlphaValue downgrades from buy to add.Travis Perkins: Panmure Gordon keeps buy rating and 1,200p target.Trinity Mirror: Panmure Gordon keeps buy rating and 90p target.Wolseley: Jefferies keeps hold rating and 2,340p target.WPP: UBS downgrades from buy to neutral, target cut from 960p to 875p.BC
More News
12 Jan 2023 17:55

Arecor transfers AT307 drug to Hikma for development, regains AT282

(Alliance News) - Arecor Therapeutics PLC on Thursday said it transferred development activities for the ready-to-use injectable medicine AT307 to Hikma Pharmaceuticals PLC, and regained rights on AT282 after a product portfolio review.

Read more
3 Jan 2023 17:31

FTSE 100 ends first trading day of 2023 on upbeat note

FTSE 100 up 1.4%, FTSE 250 adds 1.5%

*

Read more
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.